Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 save search
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Published: 2024-04-24 (Crawled : 11:00) - prnewswire.com
RDHL | $0.4199 -1.85% -3.08% 4.5K
|
Health Technology
|
| O: -8.47%
H: 10.0%
C: 5.0%
covid-19 first study
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 1.78%
H: 0.0%
C: 0.0%
covid-19 sales first announcement growing roche
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
MRNA | News S | $108.85 0.89% 0.85% 23K
|
Health Technology
|
| O: 1.36%
H: 2.57%
C: 1.62%
covid-19 contract million brazil
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.54 1.27% 9
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
AVIR | $3.7 -0.8% -0.67% 0
|
Health Technology
|
| O: 3.71%
H: 3.45%
C: 2.3%
covid-19 bemnifosbuvir antiviral pharmaceuticals global trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA | News S | $108.85 0.89% 0.85% 23K
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
Published: 2024-03-22 (Crawled : 19:00) - globenewswire.com
IVVD | $2.13 -6.17% -6.57% 6
|
Manufacturing
| Email alert
Add to watchlist
vyd222 covid-19 fda authorization
Global Medical Device Connectivity Market Poised for Substantial Growth: In-Depth Analysis Reflects Impacts of COVID-19 and Predicts Surge through 2029
Published: 2024-03-21 (Crawled : 15:30) - prnewswire.com
ORCL | News | $115.34 0.22% -0.64% 7.5K
|
Technology Services
|
| O: 0.99%
H: 1.73%
C: -1.16%
MDT | $80.38 -1.12% -0.03% 0
|
Health Technology
|
| O: -0.56%
H: 0.5%
C: -0.19%
INFY | $17.04 -0.7% 0.76% 36K
|
Technology Services
|
| O: -3.06%
H: 0.76%
C: -0.76%
LTRX | $3.23 -1.67% -1.7% 44
|
Distribution Services
|
| O: 1.12%
H: 1.67%
C: 0.28%
DGII | $30.73 1.09% 1.14% 0
|
Electronic Technology
|
| O: 0.98%
H: 0.77%
C: 0.37%
CSCO | News | $48.36 0.02% 1.3M
|
Technology Services
|
| O: 0.32%
H: 0.97%
C: 0.34%
covid-19 device global medical market
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
TSOI | $0.0007 0.0% 23M
|
Manufacturing
|
| O: 10.0%
H: 18.18%
C: 9.09%
covid-19 quadramune patent natural granted international cell solutions
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 18K
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1309 240K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.09%
C: -5.9%
covid-19 drug antiviral trial
Global Cruise Industry Trends Report 2024: COVID-19 Impacts, Company Case Studies, Sector Deals, Advertisement Activity, Challenges and Opportunities
Published: 2024-02-19 (Crawled : 23:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
covid-19 company report global trends
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
GRTS | $0.8129 10.06% 9.92% 14K
|
Health Technology
|
| O: 0.89%
H: 3.42%
C: -0.88%
covid-19 update trial
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
Published: 2024-02-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
covid-19 sales drug
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 1.27% 9
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.05 15K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $26.98 -3.4% -3.44% 0
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $26.98 -3.4% -3.44% 0
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | News | $0.7001 -1.35% 76K
|
Health Technology
|
| O: 2.1%
H: 1.04%
C: -8.52%
covid-19 award candidate vaccine million nextgen study
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
BQ | $0.279 7.31% 14K
|
Consumer Non-Durables
Your saved searches
Save your searches and get alerts when important news are released.